Mastering the Art of Partnering: A Roadmap for Startup Success

27 Jul

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the competitive entrepreneurship landscape, startups often need help distinguishing themselves from the competition; they are in a race to stand out amongst the sea of meeting requests the partners receive. Investors and licensing partners continuously lament the need for startups to develop concise, cogent, and compelling messaging that nets out their value proposition and sheds some light on the team and technology.

The problem lies in the cookie-cutter, problem-solution, market-oriented pitch decks that often fail to convey a strong personal narrative and compelling story. A startup must realize it is essentially a numbers game when they embark on a global partnering initiative. They must engage in dialogue with hundreds of potential partners to find the few that will participate in the round.  To start the dialogue, you need to secure a constant flow of meetings with partners who fit your stage of development and product. Therein lies the rub, how does a startup generate a pipeline of meetings with the right players?

Crafting a Compelling Story

Startup founders must recognize that potential investors and licensing partners invest in people before they invest in products or services. Startups must recognize the immense importance of weaving a compelling story that captivates the hearts and minds of potential partners. They should build a strong personal narrative highlighting their passion and vision. This narrative should highlight the founder’s journey, the team’s expertise, and the milestones achieved, backed by validated data. A strong personal narrative resonates with investors and partners, setting the foundation for a meaningful relationship.

Knowing Your Target Audience

In the dynamic world of entrepreneurship, understanding the target audience is key to crafting an effective brand message. Entrepreneurs must identify the ten categories of investors and licensing partners that align with their stage of development and product. Tailoring the pitch and messaging to cater to potential partners’ specific needs and interests significantly increases the chances of securing valuable meetings and partnerships. A concise tagline and compelling elevator pitch enable investors to assess the startup’s value proposition swiftly, paving the way for further engagement.

Making it Easy to Say Yes

A key principle of business development is making it easy for potential partners to say yes to a meeting. Startups should proactively present the “value add” of their founder, team, and technology. Anticipating and addressing potential partner needs and concerns demonstrates professionalism and builds trust. By providing researched, relevant information, startups improve their chances of moving forward in the partnering process.

Embrace the Global Arena

Founders must recognize that staying in their geographic regions limits the number of opportunities, thus hindering the number of partners to engage with. Breaking free from geographic limitations opens the startup to wider opportunities. Expanding globally requires a strategic game plan and sufficient resources to execute a global campaign and roadshow. Adopting and understanding rudimentary sales and marketing tactics, such as identifying potential partners and establishing a meeting pipeline, is essential to achieving success on an international scale.

Patience and Persistence

Partnering is a journey that demands both patience and persistence. The partnering process is not an overnight success story. It often takes between 9 to 18 months to establish successful partnerships. Startup teams should be prepared for the ebb and flow of partner meetings while maintaining an ongoing pipeline. A dedicated staff member focused on scheduling meetings with potential partners and utilizing a Customer Relationship Management (CRM) system to track and manage the target list can help keep the process on track. LSN has just announced a Global Campaign Management product integrating the LSN partnering database with the Salesforce CRM.

Mastering the art of partnering is a critical aspect of startup success. Entrepreneurs can significantly enhance their chances of securing essential partnerships by developing a compelling storyline, understanding their target audience, expanding from regional to global, and dedicating resources to meeting engagement. Above all, patience and persistence are vital traits needed to navigate a successful global partnering campaign.

RESI-Boston-2023-September-1100px-w

 Clinials + LSN Educational Workshop = RESI Innovator’s Pitch Challenge Success

27 Jul
Maree-BeareMaree Beare Interview with Maree Beare, Founder at Clinials

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiCaitlin Dolegowski

Maree Beare, Founder at Clinials, is a sector leader in HealthTec, FemTech and BioTech innovation. In 2021, Maree launched her second innovation, a BioTech company Clinials. Clinials is an AI-Driven clinical trial participant recruitment platform based in Brisbane, Australia, and a member of BEDA (Brisbane Economic Development Agency). Maree speaks with us about being a part of BEDA’s MedTech Accelerator cohort and her introduction to Life Science Nation followed by her eventual second-place finish in the Innovator’s Pitch Challenge at RESI Boston June earlier this summer.

RESI-Boston-2023-September-1100px-w

Hot Investor Mandate: USA-Based VC Invests in Early-Stage Therapeutics, Devices, and Diagnostics Companies Globally, Seeking Promising Assets With Strong IP in Place

27 Jul

A venture capital firm that was founded in 2020 with general partners based in the USA has a $100M USD fund dedicated to early-stage life science ventures from Seed to Series A.  The initial size of investment ranges from $1-5M and the firm seeks to invest in up to 10-12 early-stage life science companies worldwide.

The firm operates under a model that differs from traditional venture capital. As a way of de-risking, the firm works closely with a CRO that provides services and guidance on clinical translation and regulatory approval to therapeutics and medical device portfolio companies. The firm also works very closely with founders. As a critical criterion, the firm prefers to assign a highly experienced CEO to their portfolio company as they strongly believe in the importance of the management team. Also, the firm mostly exits through licensing to large pharma, medtech, or services companies. They are opportunistic about other exit strategies such as IPO.

The firm focuses on therapeutics, diagnostics, and digital health. The firm will not consider digital health. For therapeutics, pre-IND products of all modalities are considered. Within diagnostics, all modalities with proof of concept are considered. The firm will consider opportunities in any indication area.

The firm prefers asset-centric products and focuses on the scientific merits of the product or technology. The firm has a strict vetting process done by a highly experienced team and prefers companies with IP in place. The firm acts as a lead and co-investor and will require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Early-Stage Evergreen Fund Seeks Medical Devices and Research Tools, Focusing on USA-Based Opportunities

27 Jul

An early-stage investment and development firm located in the US has more than $300 million in assets and operates under an “Evergreen” structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1-5M range and the firm reserves additional funds for the subsequent funding of successful companies.

The firm invests in medical devices and research tools. For medical devices, the firm prefers those that can be approved under PMA guidelines. For research tools, the firm invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management/execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan VC Invests in Innovative Medical Devices that Address Large Market Opportunities, Open to All Regulatory Pathways

27 Jul

A venture capital firm based in Taiwan solely invests in early stage medical technology ventures. The firm currently manages a fund focused on medtech investments. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Seeks Pre-Clinical Therapeutics Opportunities, With Particular Interest in Immunology and Oncology

27 Jul

An investor and venture builder invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in immunology and oncology. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe, and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

17 Startups, 7 Unicorns, and $7M of a $37M Round Raised at RESI. An interview with Thomas Farb-Horch, CEO, Thrive Bioscience

20 Jul

Thomas Forest Farb-Horch
Interview with Thomas Forest Farb-Horch, CEO and Co-Founder, Thrive Bioscience, Inc.

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti
Caitlin Dolegowski

Caitlin Dolegowski (CD): Please introduce us to Thrive Bioscience and the company’s technology.

Thomas Forest Farb-Horch (TF): Thrive Bioscience is the seventeenth company I have been involved in founding, and I am working hard to make it my eighth unicorn. We started Thrive, based in Boston, because we saw an urgent need to improve cell and tissue culture and live cell-based processes. We want to increase the likelihood of cell-based research to make it to an approved therapy.

Even though the key to many fields of life sciences, cell and tissue culture (including related cell-based experiments, cell engineering, and cell therapies) has been performed almost entirely manually and with little data and analytics.

Thrive has orders for over 50 of its instruments at an average sales price of $200,000. Major pharmaceutical companies, institutes, and medical practitioners are capturing and analyzing massive and comparable image/data sets on live cells for machine learning, breakthrough insights, and improved cell culture.

Thrive is doing for the huge field of cell biology what sequencing did for genomics – producing extensive amounts of comparable and needed data. In addition, we are “industrializing biology” by bringing knowledge-driven automation to the field.

CD: Tell us about Thrive Bioscience’s team.

TF: I am glad you ask that question, because it takes a village! Many of my unicorns have been a success because we found neglected problems that are best solved through combining deep expertise in many fields. In order to solve the lack of data, analytics, and automation in cell and tissue culture requires an integrated team that spans many disciplines – AI, image processing, databases, robotics, and many types of engineers — software, mechanical, electrical, and optical engineers.

We have a small but agile team of 24 staff. My Co-founder and Thrive’s Chief Scientific Officer, Alan Blanchard, is brilliant and hands-on, with a background in genomics, instrumentation, physics, mathematics, neural computing, and biology.

Currently, the fastest growing part of the company is now sales and marketing because our focus is on revenues. And in addition to our staff, I consider my investors, Advisory Board Members, Board Members, distributors, and consultants as part of the team. They help us immensely.

And it is not common at our stage to have a full-time General Counsel, but because there has been limited innovation in cell culture and live-cell imaging, we have amassed a portfolio of 96 patent applications of which 34 have been issued.

CD: Thrive Bioscience has been to many RESI conferences. How did you initially learn about the conference and what were you looking to accomplish at your first one?

TF: I asked around at the incubator where Thrive started, InnoVenture Labs in Beverly, MA, as well as my seed investors, which included Life Science Angels and some family offices such as the Estee Lauder family, and industry veterans. They all pointed me to RESI and I have now been at least a dozen times.

Although most of my 17 companies are in life sciences, I had spent the previous five years not in purely life science companies and I needed to get up to speed quickly on investing trends and meet investors in a very targeted way, in early-stage life sciences companies.

CD: What were you looking to accomplish at RESI when you originally registered at RESI in 2014 at Fenway Park and what have you accomplished at RESI conferences since?

TF: You beat me to it! I was going to mention that the first RESI Conference I attended and the most recent one were both in Boston! So, it was very satisfying for me to win first place in the Innovators Pitch Challenge in my hometown last month.

In fact, RESI Boston in 2014 was the very first conference I went to after founding Thrive, and the first time I went to a RESI conference. I had just started raising a Seed round, and raised about $500,000 at RESI. Pretty good for my first conference! It was very easy to meet a lot of people.

I have raised to date about $7 million out of $35 million from investors at RESI conferences. That is a significant percentage! But it takes time to get to know investors and they like to see you a few times and track your progress. You cannot expect to go once and raise everything you need, although I did very well.

And one of the most powerful aspects of RESI conferences is the number of panels and attendees from larger companies and CVC’s. At the same time as meeting investors, you can meet “strategic investors” as well. That is one of the more difficult hurdles and RESI is an excellent way to make this happen.

CD: What stage of fundraising is Thrive Bioscience in and what are you looking to accomplish now

TF: We are just finishing our Series B Convertible Note. We are already oversubscribed with $10 million and will close with more than that. I am about to start concentrating on our Series B offering which we are targeting to complete towards the end of this year and with the assistance of RESI conferences!

CD: What advice would you like to give to fellow entrepreneurs about RESI conferences?

TF: Sometimes you can have excellent results going to one RESI, but I have found you have to plan on making the effort in going to several or many RESIs. I had good results at my first one, but to get to the $7 million I raised from RESI conferences took time and persistence. Many investors do not respond the first time you contact them but I am persistent and the second, third, or fourth time I often hear from a RESI investor attendee, “Oh yeah, I have heard about you guys.” I am thinking to myself, “Yup, that is because I have messaged you at five conferences.” You have to remember that your own priorities aren’t other people’s priorities.

And, of course, when you request a meeting on the platform, it is an opportunity to tell your story – but research the investor, tailor your message, and do it concisely. It catches people’s attention when it is clear you have done your research. And remember, you do not have to answer every possible question the first time you make contact!

RESI offers you shots on goal. But you have to take advantage of each situation. You get back from RESI what you put into it. When you go to the panels, don’t sit in the back of the room! Sit right in the front row so you are the first one to hand your card to a potential investor.

I highly recommend reading Dennis Ford’s book, The Life Science Executive’s Fundraising Manifesto, which is downloadable for free. It has lots of practical advice on researching investors and approaching investors and being prepared. It is the best book I have read on fundraising and he makes it available for download without charge!

Finally, I have gotten to know some of the RESI team and you should ask them for thoughts on who to approach. They know lots about the attendees. And read the RESI newsletters! They publish mandates for free. The staff spends a lot of time making this information available to us and it is a great resource. Again, the more you put into a RESI conference, the more you are going to get out of it!

CD: Congratulations on your first-place win in RESI Boston June Innovator’s Pitch Challenge (IPC)! You’ve had some success in previous IPCs as well. What did this success bring to Thrive Bioscience?

TF: Yes, I did win before at one of the RESI-focused conferences. I am not very good at promoting my own company, but buzz does matter. RESI helps me get the word out. Hey, participating in the IPC got me this interview and I am sure I will get some inquiries from it! Thank you for interviewing me.